{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:03:20Z","timestamp":1790345000817,"version":"4.1.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To develop and validate a machine learning-based nomogram for predicting heart failure (HF) in elderly patients with relapsed\/refractory multiple myeloma (RRMM) receiving carfilzomib-based therapy, facilitating early identification and individualized clinical management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective study analyzed clinical data from 192 elderly RRMM patients treated with carfilzomib-based therapy at Shaanxi Provincial Cancer Hospital (from January 1, 2023, to December 31, 2024). Machine learning algorithms, including the Least Absolute Shrinkage and Selection Operator (LASSO) regression, Support Vector Machine (SVM), and Extreme Gradient Boosting (XGBoost), were used for variable selection. Robust predictors identified through cross-model consistency evaluation and bootstrap resampling were incorporated into a nomogram. Model performance was assessed using concordance index (C-index), calibration curves, and decision curve analysis (DCA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>HF occurred in 25.5% (49\/192) of patients. Machine learning models consistently identified coronary artery disease (CAD), hypertension, renal insufficiency, and albumin (Alb) levels as significant HF risk factors. The nomogram showed good predictive performance (C-index: 0.780, 95% CI: 0.704\u20130.841), internal calibration (Hosmer\u2013Lemeshow \u03c7\u00b2 = 1.334, <jats:italic>P<\/jats:italic> = 0.970), and external validation (Hosmer-Lemeshow \u03c7\u00b2 = 1.054, <jats:italic>P<\/jats:italic> = 0.788). DCA confirmed clinical utility across a wide range of threshold probabilities (1% to 83%), with a peak net benefit of 0.248.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study provides a practical nomogram for cardiovascular risk assessment in elderly RRMM patients receiving carfilzomib-based therapy, which may assist clinicians in early risk stratification and support tailored monitoring and management throughout treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1624680","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T05:39:23Z","timestamp":1756877963000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Machine learning-based nomogram predicts heart failure risk in elderly relapsed\/refractory multiple myeloma patients receiving carfilzomib-based therapy"],"prefix":"10.3389","volume":"15","author":[{"given":"Dan","family":"Qiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-bin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong-hui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren-an","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1185\/03007995.2015.1105202","article-title":"Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States","volume":"32","author":"Song","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp130281","article-title":"Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma","volume":"72","author":"McBride","year":"2015","journal-title":"Am J Health Syst Pharm"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11050622","article-title":"Cardiovascular organ damage and blood pressure levels predict adverse events in multiple myeloma patients undergoing carfilzomib therapy","volume":"11","author":"Bruno","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3568","article-title":"Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-medicare data set analysis","volume":"10","author":"Bishnoi","year":"2021","journal-title":"Cancer Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2020.07.006","article-title":"Heart failure with carfilzomib in patients with multiple myeloma: a meta-analysis of randomized controlled trials","volume":"27","author":"Rahman","year":"2021","journal-title":"J Card Fail"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-874396","article-title":"Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"133","author":"Facon","year":"2019","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.176","article-title":"A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)","volume":"31","author":"Hajek","year":"2017","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/ejh.12677","article-title":"\u2018Real-life\u2019 experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors","volume":"97","author":"Danhof","year":"2016","journal-title":"Eur J Haematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-020-03044-z","article-title":"A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China","volume":"113","author":"Du","year":"2021","journal-title":"Int J Hematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221104584","article-title":"Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed\/refractory multiple myeloma: a multicenter retrospective analysis","volume":"13","author":"Onda","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International society of hypertension global hypertension practice guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"B19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study","volume":"23","author":"Usmani","year":"2022","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/978-1-4614-6849-3_18","volume-title":"Applied predictive modeling","author":"Kuhn","year":"2013"},{"key":"B21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/978-1-0716-1418-1_5","volume-title":"An introduction to statistical learning with applications in R","author":"James","year":"2021"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i6","article-title":"Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests","volume":"352","author":"Vickers","year":"2016","journal-title":"BMJ"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14058","article-title":"The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials","volume":"174","author":"Robinson","year":"2016","journal-title":"Br J Haematol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.clml.2016.11.009","article-title":"Incidence and risk of cardiac events in patients with previously treated multiple myeloma versus matched patients without multiple myeloma: an observational, retrospective, cohort study","volume":"17","author":"Kistler","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2019.100663","article-title":"Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance","volume":"48","author":"Narayanan","year":"2020","journal-title":"Drug Resist Updat"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e15943","DOI":"10.7759\/cureus.15943","article-title":"Mechanisms and potential treatment options of heart failure in patients with multiple myeloma","volume":"13","author":"Proskuriakova","year":"2021","journal-title":"Cureus"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s12012-017-9429-8","article-title":"Unanticipated cardiotoxicity associated with targeted anticancer therapy in patients with hematologic Malignancies patients: natural history and risk factors","volume":"18","author":"Shah","year":"2018","journal-title":"Cardiovasc Toxicol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.735466","article-title":"Cardiovascular toxicity of carfilzomib: the real-world evidence based on the adverse event reporting system database of the FDA, the United States","volume":"8","author":"Zhai","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-021-00607-3","article-title":"Epidemiology of cardiovascular disease in Europe","volume":"19","author":"Townsend","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cardfail.2022.02.010","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure","volume":"28","year":"2022","journal-title":"J Card Fail"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14392","article-title":"Frailty alone and interactively with obesity predicts heart failure: Kuopio Ischaemic Heart Disease Risk Factor Study","volume":"10","author":"Tajik","year":"2023","journal-title":"ESC Heart Fail"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05336-w","article-title":"Prevalence, etiology and risk factors of anemia in patients with newly diagnosed cancer","volume":"28","author":"Kenar","year":"2020","journal-title":"Support Care Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2022.07.005","article-title":"Impact of the lactate dehydrogenase in association with the international staging system prognostic score in multiple myeloma patients treated in real life","volume":"45","author":"Viol","year":"2023","journal-title":"Hematol Transfus Cell Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-023-00849-z","article-title":"Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies","volume":"13","author":"El-Cheikh","year":"2023","journal-title":"Blood Cancer J"},{"key":"B36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10741-019-09831-z","article-title":"Myocardial ischemia and coronary disease in heart failure","volume":"25","author":"Pagliaro","year":"2020","journal-title":"Heart Fail Rev"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30354-1","article-title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (ARROW): interim analysis results of a randomised, phase 3 study","volume":"19","author":"Moreau","year":"2018","journal-title":"Lancet Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1113\/JP273043","article-title":"Hypertension-induced remodelling: on the interactions of cardiac risk factors","volume":"595","author":"Tomek","year":"2017","journal-title":"J Physiol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14549","article-title":"Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 aspire study","volume":"177","author":"Dimopoulos","year":"2017","journal-title":"Br J Haematol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13900","article-title":"A phase 1\/2 study of carfilzomib in Japanese patients with relapsed and\/or refractory multiple myeloma","volume":"172","author":"Watanabe","year":"2016","journal-title":"Br J Haematol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-020-09987-z","article-title":"Pathogenesis of chronic heart failure: cardiovascular aging, risk factors, comorbidities, and disease modifiers","volume":"27","author":"Triposkiadis","year":"2022","journal-title":"Heart Fail Rev"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016003269","article-title":"Cardiac and renal complications of carfilzomib in patients with multiple myeloma","volume":"1","author":"Dimopoulos","year":"2017","journal-title":"Blood Adv"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e22585","DOI":"10.7759\/cureus.22585","article-title":"Multiple myeloma and renal failure: mechanisms, diagnosis, and management","volume":"14","author":"Kundu","year":"2022","journal-title":"Cureus"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030610","article-title":"High output heart failure in multiple myeloma: pathogenetic considerations","volume":"14","author":"Carlisi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.047662","article-title":"Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib","volume":"41","author":"Wang","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3287-8","article-title":"Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study","volume":"79","author":"Quach","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-009-0841-4","article-title":"Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma","volume":"89","author":"Kim","year":"2010","journal-title":"Ann Hematol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2010.05.022","article-title":"Serum albumin concentration and heart failure risk the health, aging, and body composition study","volume":"160","author":"Gopal","year":"2010","journal-title":"Am Heart J"},{"key":"B50","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejim.2022.05.004","article-title":"Low serum albumin: a neglected predictor in patients with cardiovascular disease","volume":"102","author":"Manolis","year":"2022","journal-title":"Eur J Intern Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/antiox13060671","article-title":"Empagliflozin alleviates carfilzomib-induced cardiotoxicity in mice by modulating oxidative stress, inflammatory response, endoplasmic reticulum stress, and autophagy","volume":"13","author":"George","year":"2024","journal-title":"Antioxid (Basel)"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2022.12.005","article-title":"Cardiovascular toxicity of proteasome inhibitors: underlying mechanisms and management strategies: JACC: CardioOncology state-of-the-art review","volume":"5","author":"Georgiopoulos","year":"2023","journal-title":"JACC CardioOncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3036","article-title":"Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: A clinical consensus statement from the Heart Failure Association of the ESC","volume":"25","author":"Bayes-Genis","year":"2023","journal-title":"Eur J Heart Fail"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1624680\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T05:39:24Z","timestamp":1756877964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1624680\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":53,"alternative-id":["10.3389\/fonc.2025.1624680"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1624680","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]},"article-number":"1624680"}}